{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:52Z","timestamp":1760784232883},"reference-count":33,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","issue":"01","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Bras Ginecol Obstet"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\n            Objective\u2003Obesity is associated with an increased risk for breast cancer. Recent studies have shown that aromatase inhibitors may be less effective in women with a high body mass index (BMI). The aim of this study was to establish the relationship between the BMI and plasma estrone and estradiol levels in postmenopausal women with hormone receptor-positive breast cancer using anastrozole.<\/jats:p><jats:p>\n            Methods\u2003In this cohort study, the patients were divided into three groups according to BMI (normal weight, overweight and obese) to compare and correlate plasma hormone levels before starting anastrozole hormone therapy and three months after treatment. Plasma hormone levels were compared for age and use of chemotherapy.<\/jats:p><jats:p>\n            Results\u2003A statistically significant reduction in estrone and estradiol levels was observed between baseline and three months after starting the anastrozole treatment (p\u2009&lt;\u20090.05). There was no statistically significant difference in plasma estrone and estradiol levels among the BMI groups (p\u2009&gt;\u20090.05), but a significant reduction in plasma estrone levels was observed after three-months' treatment relative to baseline in all groups, as well as a reduction in estradiol in the obese group (p\u2009&lt;\u20090.05). The use of chemotherapy and age\u2009&gt;\u200965 years had no influence on plasma steroid levels.<\/jats:p><jats:p>\n            Conclusion\u2003Changes in estrone and estradiol levels in the studied groups were not associated with BMI, chemotherapy or age.<\/jats:p>","DOI":"10.1055\/s-0036-1597974","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T23:41:47Z","timestamp":1486770107000},"page":"14-20","source":"Crossref","is-referenced-by-count":3,"title":["Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index"],"prefix":"10.61622","volume":"39","author":[{"given":"Eduardo Borges","family":"Coscia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricene","family":"Sabha","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marli","family":"Gerenutti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Carlos","family":"Groppo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Anesthesiology and Therapeutics, Faculdade de Odontologia de Piracicaba, Universidade Estadual de Campinas, Piracicaba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane de C\u00e1ssia","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universidade de Sorocaba, Sorocaba, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"47794","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"ref1","volume-title":"Minist\u00e9rio da Sa\u00fade. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. [Estimate 2014: cancer incidence in Brazil]","year":"2014"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"R Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/gme.0b013e3181788d88","article-title":"Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer","volume":"15","author":"V G Vogel","year":"2008","journal-title":"Menopause"},{"issue":"03","key":"ref4","first-page":"122","article-title":"Correlation between anthropometric measurements and lymph node metastases in postmenopausal women with breast cancer","volume":"20","author":"K A Cintra","year":"2010","journal-title":"Rev Bras Mastol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00008469-200102000-00003","article-title":"Review of anthropometric factors and breast cancer risk","volume":"10","author":"C M Friedenreich","year":"2001","journal-title":"Eur J Cancer Prev"},{"issue":"24","key":"ref6","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","article-title":"Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer","volume":"30","author":"E J Folkerd","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1200\/JCO.2003.07.057","article-title":"Adiposity and sex hormones in postmenopausal breast cancer survivors","volume":"21","author":"A McTiernan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jnci\/djh025","article-title":"Risk factors for breast cancer according to estrogen and progesterone receptor status","volume":"96","author":"G A Colditz","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ijc.23943","article-title":"Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis","volume":"124","author":"R Suzuki","year":"2009","journal-title":"Int J Cancer"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-012-2278-z","article-title":"Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels","volume":"136","author":"C Diorio","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"04","key":"ref11","first-page":"555","article-title":"Aromatase inhibitors in breast cancer: from metastatic disease to adjuvant treatment","volume":"48","author":"E D Saad","year":"2002","journal-title":"Rev Bras Cancerol"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.2007.13.9279","article-title":"Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer","volume":"26","author":"J M Dixon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s002800000113","article-title":"Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women","volume":"46","author":"M Dowsett","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"I Sestak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1200\/JCO.2010.29.5113","article-title":"Obesity and hormone therapy in breast cancer: an unfinished puzzle","volume":"28","author":"P J Goodwin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1002\/cncr.26217","article-title":"A review of body size and breast cancer risk in Hispanic and African American women","volume":"117","author":"K R Sexton","year":"2011","journal-title":"Cancer"},{"key":"ref17","volume-title":"Breast cancer treatment","year":"2013"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"M Baum","year":"2002","journal-title":"Lancet"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ctrv.2007.11.001","article-title":"Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review","volume":"34","author":"A Eisen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"ref20","first-page":"468S","article-title":"Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors","volume":"9","author":"A U Buzdar","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003495-200868090-00007","article-title":"Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer","volume":"68","author":"M Sanford","year":"2008","journal-title":"Drugs"},{"issue":"06","key":"ref22","first-page":"2229","article-title":"The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study","volume":"6","author":"J M Dixon","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"I E Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/BD-2006-24102","article-title":"Endogenous hormones and risk of breast cancer in postmenopausal women","volume":"24","author":"S E Hankinson","year":"2005","journal-title":"Breast Dis"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1677\/erc.1.01038","article-title":"Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition","volume":"12","author":"R Kaaks","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.ejca.2014.01.007","article-title":"Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"50","author":"P E L\u00f8nning","year":"2014","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"M Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1467-789x.2001.00031.x","article-title":"Beyond body mass index","volume":"2","author":"A M Prentice","year":"2001","journal-title":"Obes Rev"},{"issue":"16","key":"ref29","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/jnci\/djg022","article-title":"Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women","volume":"95","author":"T J Key","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.breast.2003.03.001","article-title":"Obesity and breast cancer: a review of the literature","volume":"13","author":"A R Carmichael","year":"2004","journal-title":"Breast"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/en.2009-0070","article-title":"Minireview: Obesity and breast cancer: the estrogen connection","volume":"150","author":"M P Cleary","year":"2009","journal-title":"Endocrinology"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"C C Murphy","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1078155212455939","article-title":"Adherence to adjuvant endocrine therapy in women with breast cancer","volume":"19","author":"M Danilak","year":"2013","journal-title":"J Oncol Pharm Pract"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia \/ RBGO Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journalrbgo.org\/article\/estrone-and-estradiol-levels-in-breast-cancer-patients-using-anastrozole-are-not-related-to-body-mass-index\/","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0036-1597974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:06:30Z","timestamp":1721329590000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0036-1597974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":33,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2017,2,28]]},"published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0036-1597974","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}